PT - JOURNAL ARTICLE AU - Boyer, Christopher AU - Lipsitch, Marc TI - Defining and emulating target trials of the effects of postexposure vaccination using observational data AID - 10.1101/2023.05.03.23289471 DP - 2023 Jan 01 TA - medRxiv PG - 2023.05.03.23289471 4099 - http://medrxiv.org/content/early/2023/12/04/2023.05.03.23289471.short 4100 - http://medrxiv.org/content/early/2023/12/04/2023.05.03.23289471.full AB - Postexposure vaccination has the potential to prevent or modify the course of clinical disease among those exposed to a pathogen. However, due to logistical constraints, postexposure vaccine trials have been difficult to implement in practice. In place of trials, investigators have used observational data to estimate the effectiveness or optimal timing window for postexposure vaccines, but the relationship between these analyses and those that would be conducted in a trial is often unclear. Here, we define several possible target trials for postexposure vaccination and show how, under certain conditions, they can be emulated using observational data. We emphasize the importance of the incubation period and the timing of vaccination in trial design and emulation. As an example, we specify a protocol for postexposure vaccination against mpox and provide a step-by-step description of how to emulate it using data from a healthcare database or contact tracing program. We further illustrate some of the benefits of the target trial approach through simulation.Competing Interest StatementIn the past 24 months, ML has received grant support from Pfizer and consulting income from Janssen. He is Senior Advisor to the CDC's Center for Forecasting and Outbreak Analytics, but this contribution is in his academic role and does not necessarily express the views of any government entity.Funding StatementThis work was funded by Morris-Singer Fund's gift to the Center for Communicable Disease DynamicsAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesCode and data are available at: https://github.com/boyercb/pep-target-trials https://github.com/boyercb/pep-target-trials